key: cord-0939439-yrnt9x7g
authors: Bauer, Georg
title: The potential significance of high avidity IgG for protective immunity towards SARS-CoV-2
date: 2021-03-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.01.061
sha: 068df5659916ca0b344f2e80aa4214b0679779c4
doc_id: 939439
cord_uid: yrnt9x7g

BACKGROUND: Avidity is defined as the strength of binding between IgG and its specific target epitope. IgG of high avidity is established during affinity maturation. A failure to achieve high avidity IgG may result in the lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/avidity. AVIDITY AFTER SARS-COV-2 INFECTION: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 as well as with seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. CONSEQUENCES FOR VACCINATION TOWARDS SARS-COV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination into the optimization of vaccination protocols and to try to achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination also might be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases.

Avidity of IgG is determined by its affinity and denotes the strength of binding to its target epitope. High avidity is reached after affinity/avidity maturation and reflects the best fit between IgG and epitope. Avidity of IgG is low during acute infection and reaches high values several weeks or months later (Hedman et al., 1997; Bauer, 2020) . Memory B cells express and utilize high avidity IgG to establish effective anamnestic responses (Eisen, 2014) .

High avidity of neutralizing antibodies plays an important role for antibody-mediated protection towards viral infections. Protection towards viral infections and/or resultant diseases seems to fail if avidity maturation of IgG directed towards the respective viruses is incomplete. Junker and Tilly (1994) showed that low avidity of IgG towards VZV was associated with the risk of repeated chickenpox, and Martin et al. (1994) reported on the risk of pregnant women with low avidity anti-VZV IgG to acquire chickenpox. Boppana and Britt (1995) concluded that failures to generate high avidity IgG towards CMV play a role for intrauterine transmission of CMV. The conclusions derived by Boppana and Britt (1995) are in perfect agreement with the findings by Lazzarotto et al., (2009) ; Seo et al., (2009) and Kaneko et al., (2016) . Kontio et al. (2012) reported that the concentration of IgG directed towards measles virus correlated well with the avidity inherent to this IgG, and therefore concluded that waning antibody levels and low avidity might be the cause for reinfections. The significance of IgG avidity for protective immunity towards measles virus has also been demonstrated by Paunio et al. (2005) . Puschnik et al. (2013) demonstrated that IgG avidity correlates with the neutralizing capacity of IgG directed towards Dengue J o u r n a l P r e -p r o o f virus. Delgado et al. (2009) revisited the problem of vaccination towards respiratory syncytial virus (RSV) and presented evidence that the previous failure of the formalintreated vaccine was not, as generally assumed before, due to the destruction of essential epitopes by formalin. It rather was due to the failure of the vaccine to induce an antibody response of high avidity. Immunization studies with Simian human immunodeficiency virus (SHIDV) in macaques showed a strong correlation between the avidity of IgG directed towards the viral envelope protein and protection towards viral infection (Lai et al. 2007 ). These findings have been confirmed by Pegu et al. (2013) , who demonstrated that the avidity of IgG towards the envelope protein was higher in immunized animals that were protected from infection with Simian immunodeficiency virus than in nonprotected animals.

The interaction between the receptor-binding domain of SARS-CoV-2 spike protein and angiotensin converting enzyme-2 (ACE2) on target cells is the initial step in infection (Barnes et al., 2020, a, b) . The binding between RBD of SARS-CoV-2 and ACE2 is characterized by high affinity (Khatri et al., 2020) . Therefore, Khatri et al. concluded that efficient neutralization of SARS-CoV-2 would require antibodies of high avidity. The work by Khatri et al. adds to our classical concept of neutralizing antibodies the additional requirement for high affinity/avidity.

J o u r n a l P r e -p r o o f In a review published in May 2020, the author of this perspective critically evaluated 16 publications on serological findings related to the diagnosis of SARS-CoV-2 infections (Bauer, 2020) . The review outlined that the kinetic patterns of IgM and IgG responses towards SARS-CoV-2 were characterized by a high degree of variability, which did not allow to distinguish acute and past SARS-CoV-2 infections merely by determining IgM and IgG. The review i) summarized similar findings in many other viral systems; ii) proposed a model to explain the observed variability, and iii) suggested to introduce avidity determination for an unequivocal serological diagnosis. This suggestion was based on the premise that the serological response towards SARS-CoV-2 would show classical avidity maturation, as observed before for many other viruses.

The subsequent analysis of outpatients with COVID-19 and SARS-CoV-2 infection confirmed by positive PCR, led, however, to a rather unexpected result (Bauer et al., 2021 a, b) . In contrast to the regular interaction between the humoral immune system and viruses, the avidity of IgG towards SARS-CoV-2 antigens seemed to remain low in the majority of patients, even several months after the onset of clinical symptoms. Bauer et al., 2021a demonstrated that i) the avidity of IgG directed towards SARS-CoV-2 NP, RBD and S1 was increasing with time, but that ii) the final level of avidity was much lower in most sera than found for other viral systems. Importantly, however, in a few sera high avidity was reached. These essential positive controls of high avidity allowed to conclude that the low avidity found in the majority of sera was not due to trivial reasons like incompatibility of SARS-CoV-2 antigens with urea treatment during avidity determination. Bauer et al., 2021 a, defined a mode of analysis that should allow to use avidity determination for the discrimination between acute and past SARS-CoV-2 infections despite low overall avidity. In a follow-up study with 93 sera from 70 SARS-CoV-2-infected Covid-19 outpatients, the frequent J o u r n a l P r e -p r o o f incomplete avidity maturation of IgG towards SARS-CoV-2 NP, RBD and S1 was confirmed (Bauer et al., 2021 b) . This study provided evidence that the low avidity found in most cases was due to discontinuous avidity maturation after an initial increase, rather than due to unusually slow avidity maturation. (Levett et al., 2005; Fox et al., 2006) and others (Bauer, 2020) .

Our findings and conclusions are in line with the reports from several other groups.

Strömer et al. 2020 a, b also describe predominantly occurring low avidity IgG towards SARS-CoV-antigens, while using a prototype version as well as the final version of the same assay system as used by us. Liu et al. 2020 reported that IgG towards S1 and RBD of SARS-CoV-2 showed avidity indices below 0.3 within the first 45 days after onset of disease, except for one serum with an avidity index of about 0.8 before day 10.

Benner et al. 2020 stated i) that antibody avidity increased over duration of infection and remained elevated and ii) that antibody avidity correlated with duration of J o u r n a l P r e -p r o o f infection and higher neutralizing titers. However, the DC50 values for urea during avidity determination, as shown for convalescent sera in their study, had a median between 4-5 M for IgG towards the spike protein and 6 M for NP. These values indicate that at 7 M urea, which is the discriminative concentration used in our studies, an avidity index below 0.5 would have been determined for most sera.

Therefore, despite the measurable avidity maturation, these sera remained at low or borderline avidity.

Klein et al., 2020 show in their Figure 2B that the vast majority of their 126 convalescent sera were below an avidity index of 0.4 at 7 M urea, with the exception of three sera. Luo et al., 2020 report on an increase with time in the avidity of IgG towards SARS-CoV-2 RBD. This kinetics is definitely useful for the differentiation between acute and past SARS-CoV-2 infections. However, as the assay had been performed with 3 M urea, the high avidity indices measured are converted to the low avidity range, when 7 M urea is used instead of 3 M. Therefore, their finding is also supporting the view that avidity maturation is frequently at a low level, which is best explained by incomplete avidity maturation, according to our findings.

Incomplete avidity maturation was not only found for the serological response towards SARS-CoV-2, but also for the immune responses towards four seasonal coronaviruses (Bauer et al., 2020 a, b) . It is also known that the immune responses towards the seasonal coronaviruses are characterized by a relatively rapid decline after an initial burst (Callow et al., 1990; Edrige et al., 2020) . It seems that these two characteristics of the immune response towards seasonal coronaviruses, i. e. declining antibody concentrations and frequent low avidity, are connected with the J o u r n a l P r e -p r o o f high probability of repeated waves of reinfections with these viruses (Edrige et al., 2020; Galanti and Shaman, 2020) .

Revisiting the data published for SARS CoV-1, where complete avidity maturation had been claimed (Chan et al., 2005) , revealed that the analysis had been performed with 4 M urea. This low concentration of urea does not lead to sharp discrimination between low and high avidity like 7 M urea that has been established as a standard concentration in most other studies. Therefore, the humoral response towards SARS CoV-1 also seems to be restricted to IgG of lower avidity.

Taken together, these data allow to speculate that coronaviruses interfere with avidity maturation to ensure incomplete protection towards reinfection, thus allowing a replication style that is based on repeated waves of infection in their host population.

Incomplete avidity maturation after SARS-CoV-2 infection, in combination with waning IgG titers, might prevent the establishment of herd immunity and thus potentially enable repeated cycles of reinfection. Reinfections with SARS-CoV-2, despite specific humoral immune responses after primary infection, have been reported in the meantime (Overbaugh, 2020; Tillett et al., 2020; Gupta et al., 2020) . . The concept of coronavirus strategy to render immune responses nonprotective, combined with the biophysical data on high affinity between SARS-CoV-2 RBD and its cellular receptor allow to propose that vaccination should induce certain qualities of IgG, in order to establish truly protective immunity. Vaccination programs should achieve:

J o u r n a l P r e -p r o o f i) Sufficiently high and long-lasting IgG concentrations that specifically target viral structures that are relevant for binding to cellular receptors, such as RBD;

ii) completed avidity maturation of such neutralizing IgG towards SARS-CoV-2, and iii) the potential of these antibodies to prevent the binding of the virus to the cells.

The suggested goal, therefore, is that immunization achieves a response that outcompetes the quality of the immune response reached after natural infection. (Nair et al., 2009; Re et al., 2010) . Therefore, the answer to the previous question is, that vaccination towards SARS-CoV-2 with defined antigens might provide an optimal concentration of antigen. Moreover, it would occur independent of potential negative immunomodulatory effects that are associated with viral infection. Therefore, the induction of high avidity protective IgG through vaccination seems to be feasible.

In this respect, it is encouraging to see that the mRNA-based vaccine BNT162b1 elicits antibody titers that are much higher than the titers reached after natural J o u r n a l P r e -p r o o f infection (Mulligan et al, 2020; Şahin et al., 2020) . Avidity determination should now clarify whether high avidity has been achieved as well in these studies.

whether protection towards Covid-19 through immunization towards SARS-CoV-2 is based on sterile immunity or whether the state of protection towards disease is paralleled by limited replication of virus that is not sufficient to establish disease. The resolution of these questions may be instrumental for further understanding and control of the spreading of SARS-CoV-2 in the human population.

Please find more details related to immunological protection towards infections, affinity and avidity, as well as proposals for the experimental evaluation of the concepts presented in this Perspective under Supplementary Material.

The financial support for publication fees by the Medical Faculty of the University of Freiburg is acknowledged.

Georg Bauer is coinventor for a pending patent application describing a method to determine the avidity of antibodies towards several SARS-CoV-2 antigens in one assay ("Verfahren zur Bestimmung der Avidität von gegen Coronavirus gerichteten Antikörpern sowie hierzu geeignete Testkits " (EP 2019/2550)). 

In discussions, the term "immune system" is often taken literally, assuming that a specific antibody response elicited by the immune system would always lead to complete establishment of "immunity". However, the term "immunity" implies a strong protection towards infection (reinfection) and/or disease caused by the agent that had induced immunity before. However, not every humoral response leads to protective immunity necessarily. The present discussion on herd immunity and immunity towards SARS CoV-2 is sometimes dominated by this linguistic trap, which may lead to unprecise arguments and conclusions.

Viruses utilize distinct structures on the surface of target cells for binding and subsequent onset of infection. In the case of SARS CoV-2, the interaction between the receptor-binding domain of the spike protein with angiotensin converting enzyme-2 (ACE2) on the target cells is the initial step in infection (Barnes et al., a, b) .

The term "neutralizing antibody" is often applied when classical neutralization tests confirm that preincubation of an antibody with a virus results in the prevention of subsequent infection of susceptible test cells in vitro. Without question, these tests do define antibodies that target the viral structures relevant for binding of the virus to its target. Therefore, they provide essential and valuable information on specific recognition of viruses by antibodies and biological consequences thereof.

Prevention of infection in a test system, where virus and antibodies had a chance to interact before addition of the mixture to target cells does, however, not necessarily allow to imply that a neutralizing effect of the same strength as achieved in vitro could be achieved in vivo. Under in vivo conditions, the competing effects between affinity of the virus to the relevant cellular receptors and affinity of the antibodies towards the relevant surface proteins of the virus will determine whether neutralization of the virus, i, e. prevention of infection and spreading, can finally be achieved.

These theoretical considerations allow to predict that the affinity/avidity of IgG which specifically recognizes essential structures of the virus that are essential for its binding to cells, might finally determine whether they are neutralizing and protective.

On the first sight, these considerations might be regarded as being merely theoretical or academic. However, their practical significance for SARS-CoV-2 infection can be deduced from published work (Khatri et al., 2020) . Khatri et al. determined high affinity of binding between RBD of SARS-CoV-2 and ACE2 on the target cells. They therefore concluded that protective neutralizing IgG towards SARS-CoV-2 should be of high avidity. Their conclusion extends our conceptional understanding of neutralizing antibodies and is in line with our statement that additional avidity testing of neutralizing antibodies might add valuable information to the understanding of their biological effectiveness.

It is easily conceivable that anamnestic responses directed towards reinfection or infection after successful vaccination require the potential to establish the generation of protective IgG with high avidity, as there might be a race between viral replication and establishment of an optimal immunoprotective state. In the light of these considerations it is not unexpected that completed affinity/avidity maturation seems to be a prerequisite for the generation of memory B cells (Eisen, 2014) .

After the primary steps during a humoral immune response, B cells expressing IgG directed specifically towards defined epitopes undergo further processes that result in the affinity maturation of the IgG population generated by these B cells. These IgG populations are then produced in higher concentrations by plasma cells derived from the B cells that have undergone affinity maturation of IgG (Eisen and Siskind, 1964; Foote and Milstein, 1991; Hedman et al., 1997; Hazel, 2007) . Affinity maturation of IgG is based on repeated cycles of hypermutations of the variable region of IgG, clonal selection and proliferation of B cells with IgG of higher affinity. These biological processes take place in the germinal centers of secondary lymphoid organs. At the end of this process, specific IgG with the best fit to the epitope, i. e. a high affinity IgG population, is established. Fast binding to the target, and subsequent high strength of binding to the target ("avidity"), are two cooperating features of high affinity. Both features are determined by the efficient fit between IgG and epitope. As the strength of binding (i. e. avidity) can be easier measured than affinity with its two distinct features, avidity determination is used in routine serological diagnostics as an estimation of overall affinity.

Avidity determination requires a quantitative test system for the determination of specifically binding IgG. Assays are performed in duplicate. After the incubation between serum and the test system, the diluted serum is washed away by buffer.

One of the two assays is then processed for quantitation of bound IgG as usual, whereas the second assay is treated with defined concentrations of chaotropic agents like urea for defined time. After a washing step, this assay is also further processed like its partner assay. The comparison of the quantitative results between J o u r n a l P r e -p r o o f the urea-treated and the untreated assays allows to quantitate the percentage of bound IgG that has remained bound despite the treatment with urea. This value is called avidity index and is an indication of the degree of avidity maturation.

Low avidity of IgG, typical for acute infection is usually below an avidity index of 0.5, whereas high avidity IgG can reach values up to an index of 0.9 or even 1.

Before the establishment of an avidity test system it has to determined, whether the antigens provided can tolerate the urea concentrations used.

It also has to be avoided to work with a suboptimal amount of test antigen. In the case of limited antigen availability, sera with either uniformly high or low avidity IgG can be easily discriminated from each other. However, the procession of a serum taken during avidity maturation, which contains IgG populations of different avidity, will lead to overestimation of the IgG population with high avidity, as these antibodies will preferentially bind to the antigen and therefore the low avidity antibodies will be competed out.

Sera from persons taking part in phase III vaccination studies should be instrumental to verify or falsify the conclusions presented in this perspective:

If our conclusions are meaningful, sera taken from immunized persons that were subsequently actually protected towards Covid-19, should contain IgG towards RBD/S1 of SARS CoV-1 that is significantly higher in avidity than IgG towards RBD/S1 in sera from the low percentage of vaccinated people that acquired Covid-19 despite vaccination. This comparison requires that the sera from both groups were collected at the same time after vaccination. It is also conceivable that the small percentage of persons that were unprotected towards SARS-CoV-2 infection despite J o u r n a l P r e -p r o o f vaccination and developed Covid-19 will show a booster reaction, resulting in a later increase in respective avidities Sera from persons in the placebo control group that acquired Covid-19 can be expected to show low or borderline avidity of IgG towards RBD/S1 as well as NP of SARS-CoV-2, in line with our previous findings.

The kinetic study of avidity maturation of IgG towards RBD/S1 of SARS-CoV-2 after vaccination with varying doses and time intervals might result in valuable information for an optimal vaccination scheme. These studies should clarify whether the same vaccination scheme is optimal for all age groups. It is also conceivable that the efficiency of the immune response especially in the elderly is not only determined by the degree of avidity maturation achieved, but also by the potentially reduced B cell immune repertoire of this age group (Paschold et al., 2021) .

The measurement of avidity of IgG towards NP of SARS-CoV-2 in immunized persons that had been protected from Covid-19 despite contacts to SARS-CoV-2 after vaccination should allow to clarify whether protective immunity towards SARS-CoV-2 can be characterized as sterile immunity or not. If sterile immunity was achieved, no immunological footprint of infecting SARS-CoV-2 (for example IgG towards NP) should be detectable in persons protected towards Covid-19 by vaccination. If immunity was not sterile and protecting only towards disease, while allowing limited replication of the virus, IgG towards NP should be detectable as well.

Such information might be of importance for dissecting protection towards disease from protection towards infection, as well as for excluding or proofing potential spreading of virus from vaccinated people that were protected from disease. The conclusiveness of these analyses will depend on the availability of sera taken at precisely determined time points related to vaccination and eventual disease. The J o u r n a l P r e -p r o o f

2021 a, under revision. Preprint deposited at the server of the World Health Organization

The serological response to SARS corona virus-2 is characterized by frequent incomplete maturation of functional affinity (avidity). Sci Reports, under review

Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals

SARS-CoV-2 antibody avidity responses in covid-19 patients and convalescent plasma donors

Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection

Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with west nile virus

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Lynch KL Kinetics of SARS-CoV-2 Antibody avidity maturation and association with disease severity

Occcurence of chickenpox during pregnancy in women seropositive for varicella-zoster virus

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection

Understanding protection from SARS CoV-2 by studying reinfection

IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy

Antibodies with high avidity to the gp120 envelope protein in protection from Simian Immunodeficiency Virus SIVmac251. Acquisition in an immunization regimen that mimics the RV-144 Thai Trial

Correlation between Dengue-specific neutralizing antibodies and serum avidity in primary and secondary Dengue virus 3 natural infections in humans

Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy

Diagnostic Relevance of Immunoglobulin G Avidity for Hepatitis A Virus

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 Tcell responses

Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera

Kinetics of nucleo-and spike protein-specific immunoglobulin G and of virusneutralizing antibodies after SARS-CoV-2 infection

Genomic necessary quantitative test systems for avidity determination of IgG towards NP

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Blocking of the high-affinity interaction-synapse between SARS CoV-2 spike and human ACE2 proteins likely requires multiple highaffinity antibodies: an immune perspective

Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses

Variations in the affinities of antibodies during the immune response

Clinical utility of avidity assays

Avidity of IgG in serodiagnosis of infectious diseases

SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19

The potential significance of high avidity IgG for protective immunity towards SARS-CoV-2 Georg Bauer 1) Institute of Virology, Medical Center -University of Freiburg 2) Faculty of Medicine, University of Freiburg, Freiburg, Germany